Omega-3 Index and Cardiovascular Health

Overview

Journal Nutrients

Date 2014 Feb 26

PMID 24566438

Citations 52

Authors

Clemens von Schacky

Affiliations

Soon will be listed here.

Abstract

Recent large trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the cardiovascular field did not demonstrate a beneficial effect in terms of reductions of clinical endpoints like total mortality, sudden cardiac arrest or other major adverse cardiac events. Pertinent guidelines do not uniformly recommend EPA + DHA for cardiac patients. In contrast, in epidemiologic findings, higher blood levels of EPA + DHA were consistently associated with a lower risk for the endpoints mentioned. Because of low biological and analytical variability, a standardized analytical procedure, a large database and for other reasons, blood levels of EPA + DHA are frequently assessed in erythrocytes, using the HS-Omega-3 Index® methodology. A low Omega-3 Index fulfills the current criteria for a novel cardiovascular risk factor. Neutral results of intervention trials can be explained by issues of bioavailability and trial design that surfaced after the trials were initiated. In the future, incorporating the Omega-3 Index into trial designs by recruiting participants with a low Omega-3 Index and treating them within a pre-specified target range (e.g., 8%-11%), will make more efficient trials possible and provide clearer answers to the questions asked than previously possible.

Citing Articles

Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis.

Kim J, Kong S, Jung E, Cho Y J Clin Med. 2025; 14(1.

PMID: 39797109 PMC: 11722046. DOI: 10.3390/jcm14010026.

The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp....

Sun G, Fuller H, Fenton H, Race A, Downing A, Rees C J Nutr. 2024; 155(2):549-558.

PMID: 39675479 PMC: 7617434. DOI: 10.1016/j.tjnut.2024.12.004.

Effect of FADS1 SNPs rs174546, rs174547 and rs174550 on blood fatty acid profiles and plasma free oxylipins.

Rabehl M, Wei Z, Leineweber C, Enssle J, Rothe M, Jung A Front Nutr. 2024; 11:1356986.

PMID: 39021601 PMC: 11253720. DOI: 10.3389/fnut.2024.1356986.

Omega-3 Index as a Sport Biomarker: Implications for Cardiovascular Health, Injury Prevention, and Athletic Performance.

Medoro A, Buonsenso A, Centorbi M, Calcagno G, Scapagnini G, Fiorilli G J Funct Morphol Kinesiol. 2024; 9(2).

PMID: 38804457 PMC: 11197025. DOI: 10.3390/jfmk9020091.

Urinary Metabolite Profiling to Non-Invasively Monitor the Omega-3 Index: An Exploratory Secondary Analysis of a Randomized Clinical Trial in Young Adults.

MacIntyre B, Shanmuganathan M, Klingel S, Kroezen Z, Helmeczi E, Seoh N Metabolites. 2023; 13(10).

PMID: 37887396 PMC: 10608872. DOI: 10.3390/metabo13101071.

References

Carney R, Freedland K, Stein P, Steinmeyer B, Harris W, Rubin E . Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosom Med. 2010; 72(8):748-54. PMC: 2950909. DOI: 10.1097/PSY.0b013e3181eff148. View

Shearer G, Chen J, Chen Y, Harris W . Myocardial infarction does not affect fatty-acid profiles in rats. Prostaglandins Leukot Essent Fatty Acids. 2009; 81(5-6):411-6. PMC: 2787907. DOI: 10.1016/j.plefa.2009.08.002. View

Harris W, Pottala J, Sands S, Jones P . Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr. 2007; 86(6):1621-5. DOI: 10.1093/ajcn/86.5.1621. View

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M . European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted.... Eur Heart J. 2012; 33(13):1635-701. DOI: 10.1093/eurheartj/ehs092. View

Helfand M, Buckley D, Freeman M, Fu R, Rogers K, Fleming C . Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(7):496-507. DOI: 10.7326/0003-4819-151-7-200910060-00010. View

Archer E, Hand G, Blair S . Validity of U.S. nutritional surveillance:National Health and Nutrition Examination Survey caloric energy intake data, 1971-2010. PLoS One. 2013; 8(10):e76632. PMC: 3793920. DOI: 10.1371/journal.pone.0076632. View

Harris W, von Schacky C . The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev Med. 2004; 39(1):212-20. DOI: 10.1016/j.ypmed.2004.02.030. View

von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H . The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999; 130(7):554-62. DOI: 10.7326/0003-4819-130-7-199904060-00003. View

An W, Son Y, Kim S, Kim K, Bae H, Lee S . Association of adiponectin and leptin with serum lipids and erythrocyte omega-3 and omega-6 fatty acids in dialysis patients. Clin Nephrol. 2011; 75(3):195-203. DOI: 10.5414/cnp75195. View

10.

Schuchardt J, Hahn A . Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013; 89(1):1-8. DOI: 10.1016/j.plefa.2013.03.010. View

11.

Sands S, Reid K, Windsor S, Harris W . The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids. 2005; 40(4):343-7. DOI: 10.1007/s11745-006-1392-2. View

12.

Roncaglioni M, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P . n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013; 368(19):1800-8. DOI: 10.1056/NEJMoa1205409. View

13.

Smith Jr S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B . AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124(22):2458-73. DOI: 10.1161/CIR.0b013e318235eb4d. View

14.

Aarsetoey H, Aarsetoey R, Lindner T, Staines H, Harris W, Nilsen D . Low levels of the omega-3 index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids. 2011; 46(2):151-61. PMC: 3038230. DOI: 10.1007/s11745-010-3511-3. View

15.

Krul E, Lemke S, Mukherjea R, Taylor M, Goldstein D, Su H . Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content. Prostaglandins Leukot Essent Fatty Acids. 2011; 86(1-2):51-9. DOI: 10.1016/j.plefa.2011.10.005. View

16.

An W, Lee S, Son Y, Kim S, Kim K, Han J . Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot Essent Fatty Acids. 2011; 86(1-2):29-34. DOI: 10.1016/j.plefa.2011.10.009. View

17.

Wu J, Lemaitre R, King I, Song X, Sacks F, Rimm E . Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2012; 125(9):1084-93. PMC: 3302663. DOI: 10.1161/CIRCULATIONAHA.111.062653. View

18.

Jo S, An W, Park Y . Erythrocyte n-3 polyunsaturated fatty acids and the risk of type 2 diabetes in Koreans: a case-control study. Ann Nutr Metab. 2013; 63(4):283-90. DOI: 10.1159/000357018. View

19.

Davidson M, Johnson J, Rooney M, Kyle M, Kling D . A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2013; 6(6):573-84. DOI: 10.1016/j.jacl.2012.01.002. View

20.

Shearer G, Pottala J, Hansen S, Brandenburg V, Harris W . Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res. 2012; 53(11):2429-35. PMC: 3466011. DOI: 10.1194/jlr.P022392. View